BNP Paribas Arbitrage SA increased its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 75.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,821 shares of the medical instruments supplier’s stock after purchasing an additional 12,816 shares during the quarter. BNP Paribas Arbitrage SA owned approximately 0.05% of OraSure Technologies worth $671,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in OraSure Technologies by 6.9% during the second quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock worth $28,305,000 after purchasing an additional 106,326 shares during the last quarter. Federated Investors Inc. PA boosted its holdings in OraSure Technologies by 505.6% during the second quarter. Federated Investors Inc. PA now owns 312,595 shares of the medical instruments supplier’s stock worth $5,395,000 after purchasing an additional 260,977 shares during the last quarter. Chicago Equity Partners LLC boosted its holdings in OraSure Technologies by 38.3% during the second quarter. Chicago Equity Partners LLC now owns 78,430 shares of the medical instruments supplier’s stock worth $1,354,000 after purchasing an additional 21,730 shares during the last quarter. USA Financial Portformulas Corp boosted its holdings in OraSure Technologies by 31.0% during the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock worth $978,000 after purchasing an additional 13,421 shares during the last quarter. Finally, 361 Capital LLC boosted its holdings in OraSure Technologies by 59.9% during the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 10,107 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

In other OraSure Technologies news, Director Mara G. Aspinall purchased 5,000 shares of the stock in a transaction dated Tuesday, November 7th. The shares were bought at an average price of $14.23 per share, with a total value of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $71,150. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

OraSure Technologies, Inc. (OSUR) opened at $16.44 on Wednesday. The firm has a market cap of $1,011.61, a PE ratio of 32.08, a price-to-earnings-growth ratio of 3.20 and a beta of 1.28. OraSure Technologies, Inc. has a 52 week low of $8.39 and a 52 week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The firm had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $40.87 million. During the same period in the previous year, the company earned $0.11 earnings per share. The company’s quarterly revenue was up 31.0% on a year-over-year basis. analysts expect that OraSure Technologies, Inc. will post 0.42 EPS for the current fiscal year.

A number of research analysts have weighed in on OSUR shares. Zacks Investment Research cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Friday, September 8th. Jefferies Group reiterated a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 12th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 19th. Finally, ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $18.21.

ILLEGAL ACTIVITY WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/06/bnp-paribas-arbitrage-sa-has-671000-position-in-orasure-technologies-inc-osur.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.